Payment overview · 2025
General Payments
$1,069.44
52 reported records · 17 companies
Healthcare provider profile · identity verified
Darrell Shawn Surratt, MD
Allopathic & Osteopathic Physicians|Family Medicine · BAINBRIDGE, GA · NPI 1972570943
Verified facts
What the public records show
CMS Open Payments records show Darrell Shawn Surratt, MD received $1,069.44 in general payments during 2025 across 52 reported records.
Novo Nordisk Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $216.01 | 20.2% | 8 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $110.57 | 10.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.67 | 9.6% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $96.50 | 9.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.41 | 8.8% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $89.17 | 8.3% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.84 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.12 | 5.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.01 | 5.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.76 | 4.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.51 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.23 | 2.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.03 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.46 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.62 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.04 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,069.44 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $176.95 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $140.26 | 6 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $110.57 | 6 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $89.17 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.88 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $88.88 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $64.84 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.12 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.01 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.00 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 803 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 94 |
| Gabapentin | Gabapentin | 485 | 87 |
| Furosemide | Furosemide | 444 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 76 |
| Alprazolam | Alprazolam | 386 | 46 |
| Potassium Chloride | Potassium Chloride | 321 | 64 |
| Losartan Potassium | Losartan Potassium | 318 | 55 |
| Omeprazole | Omeprazole | 295 | 59 |
| Celecoxib | Celecoxib | 282 | 49 |
| Lisinopril | Lisinopril | 269 | 52 |
| Metformin Hcl | Metformin Hcl | 267 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 28 |
| Carvedilol | Carvedilol | 233 | 32 |
| Tramadol Hcl | Tramadol Hcl | 222 | 40 |
| Trazodone Hcl | Trazodone Hcl | 211 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 42 |
| Meloxicam | Meloxicam | 192 | 32 |
| Eliquis | Apixaban | 190 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 184 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 23 |
| Levetiracetam | Levetiracetam | 153 | 12 |
| Azithromycin | Azithromycin | 152 | 95 |
| Montelukast Sodium | Montelukast Sodium | 149 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 29 |
| Fluconazole | Fluconazole | 146 | 49 |
| Prednisone | Prednisone | 145 | 68 |
| Ondansetron Odt | Ondansetron | 144 | 44 |
| Pregabalin | Pregabalin | 140 | 26 |
| Simvastatin | Simvastatin | 136 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 31 |
| Promethazine Hcl | Promethazine Hcl | 123 | 15 |
| Sertraline Hcl | Sertraline Hcl | 120 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 114 | 75 |
| Famotidine | Famotidine | 113 | 21 |
| Ozempic | Semaglutide | 112 | 15 |
| Risperidone | Risperidone | 110 | suppressed |
| Amoxicillin | Amoxicillin | 108 | 74 |
| Linzess | Linaclotide | 108 | 27 |
| Mounjaro | Tirzepatide | 98 | 15 |
| Bumetanide | Bumetanide | 93 | 23 |
| Myrbetriq | Mirabegron | 93 | 14 |
| Dexamethasone | Dexamethasone | 92 | 62 |
| Glimepiride | Glimepiride | 92 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 33 |
| Atenolol | Atenolol | 89 | 17 |
| Ibuprofen | Ibuprofen | 83 | 20 |
| Primidone | Primidone | 83 | 12 |
| Clonazepam | Clonazepam | 81 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 11 |
| Cefdinir | Cefdinir | 80 | 52 |
| Memantine Hcl | Memantine Hcl | 80 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 33 |
| Clonidine Hcl | Clonidine Hcl | 76 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | suppressed |
| Mirtazapine | Mirtazapine | 70 | suppressed |
| Allopurinol | Allopurinol | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 65 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 27 |
| Lorazepam | Lorazepam | 65 | 13 |
| Baclofen | Baclofen | 64 | suppressed |
| Chlorthalidone | Chlorthalidone | 63 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 16 |
| Methocarbamol | Methocarbamol | 61 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 32 |
| Metformin Hcl Er | Metformin Hcl | 57 | 11 |
| Glipizide Er | Glipizide | 56 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Meclizine Hcl | Meclizine Hcl | 55 | 25 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 11 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Spironolactone | Spironolactone | 41 | 13 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Colchicine | Colchicine | 36 | 11 |
| Nystatin | Nystatin | 36 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 33 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 21 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Edarbi | Azilsartan Medoxomil | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,069.44 · 52 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, HETLIOZ, JARDIANCE, Kerendia, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error